#VisualAbstract Ivosidenib or enasidenib combined with intensive chemotherapy were well-tolerated and showed encouraging clinical activity in newly diagnosed mIDH1/mIDH2 acute myeloid leukemia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.